Lin BioScience’s LBS-007 Secures the US FDA’s Fast Track Designation to Treat Acute Myeloid Leukemia
Shots:
- The US FDA has granted Fast Track Designation to the companys’ LBS-007 for treating acute myeloid leukemia
- LBS-007 is being investigated under the P-I/II dose escalation and expansion trial for its safety & tolerability to treat patients with relapsed or resistant acute leukaemias
- LBS-007 is a natural non-ATP cell cycle inhibitor that works by targeting CDC7 kinase activity to inhibit tumor cell proliferation and induce cancer cell death. Preclinical studies have shown strong activity against leukemia and solid tumors
Ref: Lin BioScience | Image: Lin BioScience
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
